Health

Amicus Therapeutics and Teva settle patent dispute

Article Image

Amicus Therapeutics (NASDAQ:FOLD) has announced a resolution to its patent litigation case with Teva Pharmaceuticals (NYSE:TEVA) through a new license agreement.

The dispute arose following Teva’s submission of an Abbreviated New Drug Application (ANDA) to market a generic version of the drug Galafold® (migalastat) 123 mg oral capsules, which was contested by Amicus due to patent infringement concerns.

Under the terms of the agreement, Teva will be granted a non-exclusive license to commercialize its generic Galafold in the United States starting in January 2037 or earlier.

In exchange, Amicus will drop its pending litigation against Teva.

While the settlement with Teva is complete, Amicus's patent disputes with Aurobindo Pharma and Lupin Pharmaceuticals will continue.

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relates to your unique circumstances. Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of, or reliance on the information provided directly or indirectly by use of this platform.

Publisher
Grafa